Teva CEO: "Content" with 2/3 access of payers for migraine drug Ajovy
February 13, 2019 at 10:21 AM EST
Teva Pharmaceutical Industries is "content" with having its new migraine drug Ajovy covered by nearly two-thirds of payers in the United States, Chief Executive Kare Schultz told Reuters on Wednesday.
